STAT Plus: Justice Department probes Sanofi and GlaxoSmithKline over possible carcinogen in Zantac pills
The Department of Justice has started investigating whether drug makers failed to disclose information about a possible carcinogen in versions of a popular heartburn drug called ranitidine, most commonly known as Zantac, that were sold to the U.S. government.
Two companies — Sanofi (SNY) and GlaxoSmithKline (GSK) — disclosed in securities filings last week that they received so-called civil investigative demands in June for information indicating potential violations of the False Claims Act, which suggests authorities are probing whether the drug makers submitted false claims to government agencies for reimbursement.
Continue to STAT Plus to read the full story…
